Nadine Houédé
A5065732872- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer survivorship and care
- Cancer, Lipids, and Metabolism
- Multiple and Secondary Primary Cancers
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Nutrition and Health in Aging
- Multiple Myeloma Research and Treatments
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer
- Cancer Diagnosis and Treatment
- Urologic and reproductive health conditions
- Bone health and treatments
- Lung Cancer Treatments and Mutations
- Fibroblast Growth Factor Research
- Frailty in Older Adults
Inserm
2016-2025
Université de Montpellier
2014-2025
Institut de Cancérologie de Bourgogne
2020-2025
Centre Hospitalier Universitaire de Nîmes
2016-2025
Institut de Recherche en Cancérologie de Montpellier
2015-2024
Centre National de la Recherche Scientifique
2024
Université de Nîmes
2014-2023
Lymphoma Study Association
2012-2022
Institut Bergonié
2009-2019
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
2016
Objective factors for making choices about the treatment of elderly patients with cancer are lacking. This investigation aimed to help physicians select appropriate treatments through identification that predict early death (< 6 months) after initiation chemotherapy treatment.Previously untreated greater than 70 years age who were scheduled first-line various types included. Baseline abbreviated comprehensive geriatric assessment (aCGA), including Mini-Mental State Exam, Timed Get Up and Go...
Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib prednisone patients mCRPC.Men progressive mCRPC after docetaxel abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to 60 mg once per day or 5 twice day. The primary end point was overall survival (OS). Bone...
To determine factors associated with early functional decline during first-line chemotherapy in older patients.Patients age ≥ 70 years receiving for cancer were prospectively considered inclusion across 12 centers France. Functional was defined as a decrease of 0.5 points on the Activities Daily Living (ADL) scale between beginning and second cycle. Factors sought from pretreatment abbreviated comprehensive geriatric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional...
Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 alterations who have progression after platinum-containing chemotherapy. The effects erdafitinib patients FGFR-altered during checkpoint inhibitors (anti-programmed cell death protein 1 [PD-1] anti-programmed ligand [PD-L1] agents) are unclear. We conducted global phase 3 trial as compared chemotherapy had...
Nivolumab is standard of care for patients with metastatic clear cell renal carcinoma (ccRCC) after failure antiangiogenic therapies, but its activity on brain metastases from ccRCC remains unknown, because these were excluded pivotal studies. We aimed to assess the nivolumab in this population.The GETUG-AFU 26 NIVOREN phase II trial assessed and safety who failed vascular endothelial growth factor-directed therapies (ClinicalTrials.gov identifier: NCT03013335). Patients asymptomatic...
Objective We tested the effect of dietary advice dedicated to increase intake in older patients at risk for malnutrition during chemotherapy, versus usual care, on one-year mortality. Method conducted a multicentre, open-label interventional, stratified (centre), parallel randomised controlled trial, with 1∶1 ratio, two-year follow-up. Patients were aged 70 years or treated chemotherapy solid tumour and (MNA, Mini Nutritional Assessment 17–23.5). Intervention consisted diet counselling aim...
LBA4619 Background: FGFRalt are observed in ~20% of pts with mUC. Erda is an oral selective pan-FGFR tyrosine kinase inhibitor granted accelerated approval to treat locally advanced or mUC adults susceptible FGFR3/2alt who have progressed after platinum-containing chemo. THOR (NCT03390504), a randomized phase 3 study, assessed whether erda provided survival advantage vs investigator’s choice chemo 1 2 prior treatments, including anti-PD-(L)1 agent. Methods: Pts (≥18 y) unresectable...
Summary An outcome‐adaptive Bayesian design is proposed for choosing the optimal dose pair of a chemotherapeutic agent and biological used in combination phase I/II clinical trial. Patient outcome characterized as vector two ordinal variables accounting toxicity treatment efficacy. A generalization Aranda‐Ordaz model (1981, Biometrika 68 , 357–363) marginal probabilities functions pair, Gaussian copula assumed to obtain joint distributions. Numerical utilities all elementary patient...
Abstract Background During cancer, coping strategies adopted by patients with prostate cancer and their spouses have an effect on own emotional state quality of life (QoL). However, the effects used a member couple well‐being other are unknown. The aim this study is to examine dyadic QoL couples dealing cancer. Methods Ninety‐nine completed various self‐questionnaires assess psychological physical QoL, anxiety, depressive symptoms, at beginning, middle, end primary treatment. Results...